GlassScriptPhysician profile
Sybil L Sandoval
NPI 1407833106
$4,704.57
in general payments reported to CMS, 2019-2025
30 companies · $1,408 in 2025
The $1,408 reported for 2025 was more than what 89% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $716 · 2020: $208 · 2022: $585 · 2023: $848 · 2024: $940 · 2025: $1,408.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,195.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,195.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $724.94 | 2019-2025 | Entyvio, Eohilia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $521.52 | 2019-2025 | Xifaxan |
| Celgene Corporation | $429.81 | 2022-2023 | Zeposia |
| Janssen Biotech, INC. | $409.25 | 2020-2025 | Tremfya, Stelara, Simponi |
| Regeneron Healthcare Solutions, INC. | $320.25 | 2019-2025 | Dupixent |
| Gilead Sciences, INC. | $318.64 | 2019-2025 | |
| Lilly USA, LLC | $210.73 | 2020-2025 | Omvoh |
| Intercept Pharmaceuticals, INC. | $186.34 | 2019-2025 | Ocaliva |
| Madrigal Pharmaceuticals | $182.97 | 2024-2025 | Rezdiffra, Resmetirom |
| Exact Sciences Corporation | $163.10 | 2023-2025 | Cologuard Collection Kit |
| Aimmune Therapeutics, INC. | $149.77 | 2025 | Zenpep |
| Phathom Pharmaceuticals, INC. | $144.59 | 2024-2025 | Voquezna |
| Ardelyx, INC. | $136.04 | 2023-2025 | Ibsrela |
| Abbvie INC. | $135.95 | 2019-2025 | |
| Qol Medical, LLC | $130.45 | 2022-2025 | Sucraid |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $103.48 | 2019-2023 | Avsola, Amjevita |
| Astellas Pharma US INC | $71.13 | 2019-2020 | |
| Ironwood Pharmaceuticals, INC | $66.81 | 2023-2024 | Linzess |
| Ferring Pharmaceuticals INC. | $55.44 | 2023-2024 | Rebyota |
| Genzyme Corporation | $51.99 | 2022-2023 | |
| Janssen Pharmaceuticals, INC | $31.40 | 2019 | |
| Celltrion USA INC. | $29.25 | 2025 | Vegzelma |
| Sandoz INC. | $20.14 | 2024 | Hyrimoz |
| Braintree Laboratories, INC. | $18.93 | 2019 | |
| Glaxosmithkline, LLC. | $18.42 | 2019 | |
| Merck Sharp & Dohme LLC | $18.10 | 2019 | |
| Amarin Pharma, INC. | $17.62 | 2020 | |
| Shire North American Group INC | $13.22 | 2019 | |
| Genentech USA, INC. | $12.72 | 2019 | |
| Pfizer INC. | $11.57 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sybil Sandoval listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.